Examining the Phase III VAYHIT2 Trial Results for Ianalumab in Primary Immune Thrombocytopenia (ITP) from Novartis

Scheduled for:Dec 30, 2025 7:00 PM EDT

Call Duration:30 minutes

Desired Expert

A hematologist with expertise in autoimmune cytopenias, particularly ITP, and experience with B cell-directed therapies. The expert should have familiarity with emerging treatment strategies, clinical trial data interpretation, and managing patients requiring durable platelet responses with minimal treatment burden.

Interview Goal

The interview aims to explore the positive top-line results from the Phase III VAYHIT2 trial evaluating ianalumab plus eltrombopag in adults with primary immune thrombocytopenia (ITP) previously treated with corticosteroids. The discussion will focus on the clinical relevance of prolonged time to treatment failure (TTF), sustained platelet responses, the potential of ianalumab as a short-course therapy, safety considerations, and its role in reshaping long-term disease management.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.